ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to ...
The global High Content Screening Market , valued at US$1.47 billion in 2024, is forecasted to grow at a robust CAGR of 7.5%, ...
(ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF) 1 ...
Lundin Mining Corporation ("Lundin Mining" or the "Company") reports the following updated share capital and voting rights, in accordance with the Swedish Financial Instruments Trading Act: ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
1d
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology ...
Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...
Chinese auto producers are looking to boost sales in Europe while their domestic market slows down, counting on their ...
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback